Insight Molecular Diagnostics Inc.

IMDX Nasdaq CIK: 0001642380

Company Information

Industry In Vitro & In Vivo Diagnostic Substances
SIC Code 2835
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation CA
Business Address 2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
Mailing Address 2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
Phone 949-409-7600
Fiscal Year End 1231
EIN 271041563

Financial Overview

FY2025

$57.22M
Total Liabilities
$20.47M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
10-K Annual financial report March 26, 2026 View on SEC
8-K Current report of material events February 26, 2026 View on SEC
4 Insider stock transaction report February 12, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 12, 2026 View on SEC
8-K Current report of material events February 12, 2026 View on SEC
424B5 Prospectus supplement February 11, 2026 View on SEC

Annual Reports

10-K March 26, 2026
  • Strategic pivot from high-cost lab services to a scalable diagnostic kit model.
  • Rebranding of core test portfolio under the GraftAssure name to drive hospital adoption.
View Analysis

Insider Trading

BUY 1 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2835)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.